Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
Marie Marchand,N van Baren,N van Baren,P. Weynants,P. Weynants,Vincent Brichard,Vincent Brichard,Vincent Brichard,Brigitte Dreno,M H Tessier,E Rankin,Giorgio Parmiani,Flavio Arienti,Yves Humblet,A Bourlond,Romain Vanwijck,Danielle Lienard,Marc Beauduin,Pierre-Yves Dietrich,Vincenzo Russo,Joseph Kerger,Giuseppe Masucci,Elke Jäger,J. P. De Greve,J Atzpodien,Francis Brasseur,Francis Brasseur,Pierre Coulie,P. van der Bruggen,P. van der Bruggen,Thierry Boon,Thierry Boon +31 more
Reads0
Chats0
TLDR
The results suggest that injection of the MAGE‐3.A1 peptide induced tumor regression in a significant number of the patients, even though no massive CTL response was produced.Abstract:
Thirty-nine tumor-bearing patients with metastatic melanoma were treated with 3 subcutaneous injections of the MAGE-3.A1 peptide at monthly intervals. No significant toxicity was observed. Of the 25 patients who received the complete treatment, 7 displayed significant tumor regressions. All but one of these regressions involved cutaneous metastases. Three regressions were complete and 2 of these led to a disease-free state, which persisted for more than 2 years after the beginning of treatment. No evidence for a cytolytic T lymphocyte (CTL) response was found in the blood of the 4 patients who were analyzed, including 2 who displayed complete tumor regression. Our results suggest that injection of the MAGE-3.A1 peptide induced tumor regression in a significant number of the patients, even though no massive CTL response was produced.read more
Citations
More filters
Journal ArticleDOI
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
Catherine Uyttenhove,Luc Pilotte,Ivan Théate,Ivan Théate,Vincent Stroobant,Didier Colau,Nicolas Parmentier,Thierry Boon,Benoît Van den Eynde +8 more
TL;DR: It is shown that most human tumors constitutively express IDO, and that expression of IDO by immunogenic mouse tumor cells prevents their rejection by preimmunized mice, suggesting that the efficacy of therapeutic vaccination of cancer patients might be improved by concomitant administration of an IDO inhibitor.
Journal ArticleDOI
Cancer/testis antigens, gametogenesis and cancer.
TL;DR: CT antigens are being evaluated for their role in oncogenesis — recapitulation of portions of the germline gene-expression programme might contribute characteristic features to the neoplastic phenotype, including immortality, invasiveness, immune evasion, hypomethylation and metastatic capacity.
Journal ArticleDOI
Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma
Beatrice Thurner,Ina Haendle,Claudia Röder,Detlef Dieckmann,Petra Keikavoussi,Helmut Jonuleit,Armin Bender,Christian Maczek,Doris Schreiner,Peter von den Driesch,Eva B. Bröcker,Ralph M. Steinman,Alexander Enk,Eckhart Kämpgen,Gerold Schuler +14 more
TL;DR: The principle that DC “vaccines” can frequently expand tumor-specific CTLs and elicit regressions even in advanced cancer is proved and evidence for an active CD8+ CTL–tumor cell interaction in situ as well as escape by lack of tumor antigen expression is provided.
Journal ArticleDOI
Immune evasion in cancer: Mechanistic basis and therapeutic strategies
Dass S. Vinay,Elizabeth P. Ryan,Graham Pawelec,Wamidh H. Talib,John Stagg,Eyad Elkord,Terry Lichtor,William K. Decker,Richard L. Whelan,H. M. C. Shantha Kumara,Emanuela Signori,Kanya Honoki,Alexandros G. Georgakilas,Amr Amin,William G. Helferich,Chandra S. Boosani,Gunjan Guha,Maria Rosa Ciriolo,Sophie Chen,Sulma I. Mohammed,Asfar S. Azmi,W. Nicol Keith,Alan Bilsland,Dipita Bhakta,Dorota Halicka,Hiromasa Fujii,Katia Aquilano,S. Salman Ashraf,Somaira Nowsheen,Xujuan Yang,Beom K. Choi,Byoung S. Kwon +31 more
TL;DR: The advances made toward understanding the basis of cancer immune evasion are discussed, the efficacy of various therapeutic measures and targets that have been developed or are being investigated to enhance tumor rejection are summarized and some natural agents and phytochemicals merit further study.
Journal ArticleDOI
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial
Bernard Escudier,Thierry Dorval,Nathalie Chaput,Fabrice Andre,Marie-Pierre Caby,Sophie Novault,Caroline Flament,Christophe Leboulaire,Christophe Borg,Sebastian Amigorena,Catherine Boccaccio,Christian Bonnerot,Olivier Dhellin,Mojgan Movassagh,Sophie Piperno,Caroline Robert,Vincent Serra,Nancy Valente,Jean-Bernard Le Pecq,Alain Spatz,Olivier Lantz,Thomas Tursz,Eric Angevin,Laurence Zitvogel +23 more
TL;DR: The first exosome Phase I trial highlighted the feasibility of large scale exosomal MHC class II molecules production and the safety of exosomes administration.
References
More filters
Journal ArticleDOI
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
P. van der Bruggen,Catia Traversari,Patrick Chomez,Christophe Lurquin,E De Plaen,B Van den Eynde,Alexander Knuth,Thierry Boon +7 more
TL;DR: In this paper, a gene was identified that directed the expression of antigen MZ2-E on a human melanoma cell line, which belongs to a family of at least three genes.
Journal ArticleDOI
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.
Frank O. Nestle,Selma Alijagic,Michel Gilliet,Yuansheng Sun,Stephan Grabbe,Reinhard Dummer,Günter Burg,Dirk Schadendorf +7 more
TL;DR: Vaccination with autologous DCs generated from peripheral blood is a safe and promising approach in the treatment of metastatic melanoma and antigen-specific immunity was induced during DC vaccination.
Journal ArticleDOI
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
Steven A. Rosenberg,James Chih-Hsin Yang,Douglas J. Schwartzentruber,Patrick Hwu,Francesco M. Marincola,Suzanne L. Topalian,Nicholas P. Restifo,Mark E. Dudley,Susan L. Schwarz,Paul J. Spiess,John R. Wunderlich,Maria R. Parkhurst,Yutaka Kawakami,Claudia A. Seipp,Jan Einhorn,Donald E. White +15 more
TL;DR: A synthetic peptide, designed to increase binding to HLA-A2 molecules, was used as a cancer vaccine to treat patients with metastatic melanoma and, on the basis of immunologic assays, 91% of patients could be successfully immunized with this peptide.
Journal ArticleDOI
Tumor-antigens recognized by T-lymphocytes
Thierry Boon,Jean-Charles Cerottini,Benoît Van den Eynde,Pierre van der Bruggen,Aline Van Pel +4 more
TL;DR: The identification of human tumor rejection antigens opens new possibilities for systematic approaches to the specific immune therapy of cancer.
Journal ArticleDOI
Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape
Michael Hahne,Donata Rimoldi,Michael Schröter,Pedro Romero,M. Schreier,Lars E. French,Pascal Schneider,Thierry Bornand,Adriano Fontana,D. Lienard,Jean Charles Cerottini,J. Tschopp +11 more
TL;DR: In vivo, injection of FasL+ mouse melanoma cells in mice led to rapid tumor formation and tumorigenesis was delayed in Fas-deficient lpr mutant mice in which immune effector cells cannot be killed by FasL.